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Abstract 1 
 2 
Involvement of the pituitary BMP system in the modulation of prolactin 3 
(PRL) secretion regulated by somatostatin analogs, including octreotide (OCT) and 4 
pasireotide (SOM230), and a dopamine agonist, bromocriptine (BRC), were examined 5 
in GH3 cells.  GH3 cells are rat pituitary somato-lactotrope tumor cells that express 6 
somatostatin receptors (SSTRs) and BMP system molecules including BMP-4 and -6.  7 
Treatment with BMP-4 and -6 increased PRL and cAMP secretion by GH3 cells.  The 8 
BMP-4 effects were neutralized by adding a BMP-binding protein Noggin.  These 9 
findings suggest the activity of endogenous BMPs in augmenting PRL secretion by 10 
GH3 cells.  BRC and SOM230 reduced PRL secretion, but OCT failed to reduce the 11 
PRL level.  In GH3 cells activated by forskolin, BRC suppressed forskolin-induced 12 
PRL secretion with reduction in cAMP levels.  OCT did not affect forskolin-induced 13 
PRL level, while SOM230 reduced PRL secretion and PRL mRNA expression induced 14 
by forskolin.  BMP-4 treatment enhanced the reducing effect of SOM230 on 15 
forskolin-induced PRL level while BMP-4 did not affect the effects of OCT or BRC.  16 
Noggin treatment had no significant effect on the BRC actions reducing PRL levels by 17 
GH3 cells.  However, in the presence of Noggin, OCT elicited an inhibitory effect on 18 
forskolin-induced PRL secretion and PRL mRNA expression, whereas the SOM230 19 
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effect on PRL reduction was in turn impaired.  It was further found that BMP-4 and -6 1 
suppressed SSTR-2 but increased SSTR-5 mRNA expression of GH3 cells.  These 2 
findings indicate that Noggin rescues SSTR-2 but downregulates SSTR-5 by 3 
neutralizing endogenous BMP actions, leading to an increase in OCT sensitivity and a 4 
decrease in SOM230 sensitivity of GH3 cells.  In addition, BMP signaling was 5 
facilitated in GH3 cells treated with forskolin.  Collectively, these findings suggest that 6 
BMPs elicit differential actions in the regulation of PRL release dependent on cellular 7 
cAMP-PKA activity.  BMPs may play a key role in the modulation of SSTR 8 
sensitivity of somato-lactotrope cells in an autocrine/paracrine manner. 9 
10 
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Introduction 1 
 2 
BMPs, which belong to the TGF-β superfamily, were originally identified as 3 
active components in bone extracts that are capable of inducing bone formation at 4 
ectopic sites.  A variety of physiological BMP actions in many endocrine tissues, 5 
including the ovary, pituitary, thyroid and adrenal, have been discovered (Shimasaki et 6 
al., 2004; Otsuka, 2010).  There is also increasing evidence that locally produced 7 
BMPs play key roles in differentiation of the pituitary.  The BMP system is known to 8 
play important roles in initial development of the anterior pituitary (Scully and 9 
Rosenfeld, 2002).  BMP-4 is required during the first stage of pituitary organogenesis 10 
for the proliferation of Rathke’s pouch, which gives rise to Pit-1 lineage cells including 11 
lactotrope cells.  During the subsequent stages of pituitary organogenesis, inhibition of 12 
BMP-2 by fibroblast growth factor (FGF)-8 leads to differentiation of corticotrope cells 13 
(Kioussi et al., 1999; Dasen and Rosenfeld, 2001).  BMP-4 not only governs the 14 
pituitary organogenesis but also plays a key role in the pathogenesis of differentiated 15 
pituitary lineages (Giacomini et al., 2006; Labeur et al., 2010; Tsukamoto et al., 2010).   16 
Dopamine agonists (DA) are the clinical treatment of choice for prolactin 17 
(PRL)-secreting pituitary adenomas (Casanueva et al., 2006).  They control PRL 18 
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secretion and cell proliferation by interacting with the dopamine D2 receptor (D2R), 1 
which subsequently activates various transduction pathways (Missale et al., 1998).  2 
D2R agonists are efficient in the majority of cases; however, some patients with 3 
prolactinomas fail to obtain PRL normalization and reduction in tumor size even with 4 
the most potent dopamine agonist, cabergoline (Molitch, 2005; Gillam et al., 2006; 5 
Hofland et al., 2010).  These prolactinomas, resistant to DA, are usually large and/or 6 
invasive, and surgery therefore cannot be a complete curative treatment.  In such 7 
tumors poorly or partially responsive to DA, an alternative medical treatment is needed.  8 
Experimental data have demonstrated that different somatostatin receptor (SSTR) 9 
subtypes are expressed at various levels in prolactinomas, SSTR-5 being the most 10 
important in the regulation of PRL secretion (Shimon et al., 1997; Jaquet et al., 1999).  11 
A partial synergistic effect between D2R and SSTR-5 in suppressing PRL secretion has 12 
also been reported (Jaquet et al., 1999).   13 
Here we studied a unique activity of the pituitary BMP system in PRL 14 
regulation by somatostatin analogs using rat somato-lactotropinoma GH3 cells.  GH3 15 
cells express somatostatin receptors including SSTR-1, -2, -3, -4 and -5 as well as 16 
dopamine D2R (Johnston et al., 1991; Yang et al., 2005; Miyoshi et al., 2008).  In 17 
addition, we earlier reported that both GH3 cells and rat whole pituitaries express 18 
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BMP/activin type I receptors (ALK-2, -3 and -4), type II receptors (ActRII, ActRIIB 1 
and BMPRII) and Smads (Smad1, 2, 3, 4, 5, 6, 7 and 8) (Miyoshi et al., 2008).  The 2 
whole pituitary tissues also express BMP/activin ligands, including BMP-2, -4, -6, -7, 3 
activinβA/βB, and inhibinα subunits.  The predominant BMP ligands endogenously 4 
expressed in GH3 cells are reported to be BMP-4 and BMP-6 (Miyoshi et al., 2008).  5 
Based on the present findings on GH3 cells expressing both machineries for BMP 6 
system and SSTR signaling, we here propose that BMPs may play a key role in the 7 
modulation of SSTR sensitivity of pituitary tumor cells in an autocrine/paracrine 8 
manner. 9 
10 
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Materials and Methods 1 
 2 
Reagents and supplies 3 
A 1:1 mixture of Dulbecco’s Modified Eagle’s Medium/Ham F-12 medium 4 
(DMEM/F12), penicillin-streptomycin solution, forskolin (FSK), and 5 
3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma-Aldrich Corp. (St. 6 
Louis, MO).  Recombinant human BMP-4, BMP-6 and mouse Noggin were purchased 7 
from R&D Systems (Minneapolis, MN).  Bromocriptine mesylate (BRC), octreotide 8 
acetate (OCT) and pasireotide, also known as SOM230 (SOM), were provided by by 9 
Novartis International Pharmaceutical Ltd. (Basel, Switzerland).   10 
 11 
Cell culture and cAMP measurement 12 
Rat pituitary somato-lactotrope tumor GH3 cells were cultured in DMEM/F12 medium 13 
supplemented with 10% fetal calf serum (FCS) and antibiotics in a 5% CO2 atmosphere 14 
at 37°C.  GH3 cells (1 × 105 viable cells) were seeded in 24-well plates with 15 
DMEM/F12 containing 10% FCS and penicillin-streptomycin.  After preculture, the 16 
medium was changed to serum-free DMEM/F12 containing penicillin-streptomycin and 17 
0.1 mM IBMX (a specific inhibitor of phosphodiesterase activity), and then the cells 18 
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were treated with indicated concentrations and combinations of FSK, BRC, OCT, SOM, 1 
BMP-4, BMP-6 and Noggin.  After 24-h culture, the medium removed from the cells 2 
was centrifuged.  The supernatant of the culture media was collected and stored at 3 
-80°C until assay.  After acetylation of each sample, the extracellular contents of 4 
cAMP were determined by an enzyme immunoassay with assay sensitivity of 0.039 nM 5 
(Assay Designs, Inc., Ann Arbor, MI).  The intra- and inter-assay coefficients are 6.8% 6 
and 7.9%, respectively.   7 
 8 
Determination of prolactin levels 9 
GH3 cells (1 × 105 viable cells) were cultured in 24-well plates with DMEM/F12 10 
containing 10% FCS and penicillin-streptomycin.  After preculture, the medium was 11 
changed to serum-free DMEM/F12, and then the cells were treated with indicated 12 
concentrations and combinations of FSK, BRC, OCT, SOM, BMP-4, BMP-6 and 13 
Noggin.  After 24-h culture, the medium removed from the cells was centrifuged.  14 
The supernatant of the culture media was collected and stored at -80°C until assay.  15 
The levels of PRL in the cultured media were determined by a rat-specific enzyme 16 
immunoassay with assay sensitivity of 1 pg/ml (Duhau et al., 1991) (SPI-BIO, 17 
Montigny-le-Bretonneux, France).  The intra- and inter-assay coefficients are 10.6% 18 
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and 13.4%, respectively.   1 
     2 
RNA extraction and quantitative real-time PCR analysis 3 
After preculture, cells (3 × 105 viable cells) were treated with indicated concentrations 4 
of FSK, BRC, OCT, SOM, BMP-4, BMP-6 and Noggin in serum-free DMEM/F12.  5 
After 24-h culture, the medium was removed and total cellular RNA was extracted 6 
using TRIzol (Invitrogen Corp., Carlsbad, CA).  Total RNA was quantified by 7 
measuring the absorbance of the sample at 260 nm and was stored at -80°C until assay.  8 
The extracted RNA (1 μg) was subjected to RT reaction using First-Strand cDNA 9 
Synthesis System (Invitrogen Corp.) with random hexamer (2 ng/μl), reverse 10 
transcriptase (200 U) and deoxynucleotide triphosphate (dNTP; 0.5 mM) at 42°C for 50 11 
min and at 70°C for 10 min.  For the quantification of indicated mRNA levels of PRL, 12 
D2R, SSTRs, Id-1 and housekeeping gene ribosomal L19 (RPL19), real-time PCR was 13 
performed using LightCycler-FastStart DNA Master SYBR Green I system (Roche 14 
Diagnostic Co., Tokyo, Japan) under conditions of annealing at 60°C with 4 mM MgCl2, 15 
following the manufacturer’s protocol.  Accumulated levels of fluorescence for each 16 
product were analyzed by the second derivative method after melting-curve analysis 17 
(Roche Diagnostic Co.), and then, following assay validation by calculating each 18 
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amplification efficiency, the expression levels of target genes were quantified on the 1 
basis of standard curve analysis for each product.  Oligonucleotides used for RT-PCR 2 
were custom-ordered from Invitrogen Corp.  PCR primer pairs were selected from 3 
different exons of the corresponding genes as follows: PRL: 271-291 and 471-491 4 
(NM_012629); D2R: 542-562 and 851-871 (from GenBank accession No. X56065); 5 
SSTR-2: 240-260 and 559-579 (M93273); SSTR-5: 98-118 and 368-388 (L04535); and 6 
Id-1, 225-247 and 364-384 (NM_010495).  For each transcript, all treatment groups 7 
were quantified simultaneously in a single LightCycler run.  To correct for differences 8 
in RNA quality and quantity between samples, the expression levels of target gene 9 
mRNA were normalized by dividing the quantity of target gene by the quantity of 10 
RPL19 in each sample.  The raw data of each target mRNA level (/RPL19) were 11 
statistically analyzed as indicated, and then shown as fold changes in the figures.   12 
 13 
Western immunoblot analysis 14 
Cells (3 × 105 viable cells) were cultured in 12-well plates in DMEM/F12 containing 15 
penicillin-streptomycin.  After preculture, the medium was changed to serum-free 16 
DMEM/F12 and cultured for 24 h, and then the cells were treated with indicated 17 
concentrations and combinations of OCT, SOM and BMP-4.  After 1-h culture, cells 18 
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were solubilized in 100 μl RIPA lysis buffer (Upstate Biotechnology, Inc., Lake Placid, 1 
NY) containing 1 mM Na3VO4, 1 mM NaF, 2% SDS and 4% β-mercaptoethanol.  The 2 
cell lysates were then subjected to SDS-PAGE immunoblotting analysis using 3 
anti-phospho-Smad1/5/8 antibody (Cell Signaling Technology, Inc.) and anti-actin 4 
antibody (Sigma-Aldrich Co. Ltd.).  The relative integrated density of each protein 5 
band was digitized by NIH image J 1.34s. 6 
 7 
Statistical analysis 8 
All results are shown as means ± SEM of data from at least three separate experiments, 9 
each performed with triplicate samples.  The data of prolactin and cAMP levels, 10 
real-time PCR analysis and immunoblots densities were subjected to ANOVA with 11 
Tukey-Kramer’s post hoc test or unpaired t-test, when appropriate, to determine 12 
differences.  P values < 0.05 were accepted as statistically significant. 13 
14 
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Results 1 
 2 
We first examined the effects of BMPs on PRL secretion by GH3 cells for 24 3 
h.  As shown in Fig. 1A, BMP-4 and BMP-6 stimulated PRL production.  In 4 
accordance with PRL release, cAMP synthesis was also increased by treatment with 5 
BMP-4 and BMP-6.  The BMP-4 effects were neutralized by treatment with 30 ng/ml 6 
of a BMP-binding protein, Noggin.  Subsequently, we examined the effects of 7 
somatostatin analogs, including octreotide (OCT) and pasireotide (SOM230), and a 8 
dopamine agonist, bromocriptine (BRC), on PRL and cAMP levels by GH3 cells.  9 
OCT had no effects on PRL and cAMP release, while SOM and BRC suppressed PRL 10 
and cAMP levels (Fig. 1B).  To clarify the effects of OCT, SOM and BRC on PRL 11 
secretion by GH3 cells, GH3 cells were cultured in the presence of forskolin (FSK).  12 
FSK significantly activated PRL secretion with increasing cAMP level (Fig. 1C).  13 
OCT had no effect on FSK-induced PRL or cAMP level, whereas SOM showed a 14 
dose-responsive decrease of PRL as well as cAMP level (Fig. 1C).  BRC showed more 15 
efficacious suppression of FSK-induced PRL secretion as well as cAMP level.   16 
Next, BMP-4 actions on PRL secretion regulated by OCT, BRC and SOM 17 
were examined (Fig. 2A).  BMP-4 did not affect PRL secretion in GH3 cells treated 18 
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with OCT or BRC regardless of the effects of FSK.  Notably, BMP-4 treatment 1 
significantly potentiated the SOM effects reducing PRL secretion stimulated by FSK.  2 
To examine the involvement of endogenous BMP actions in PRL release by GH3 cells, 3 
cells were treated with Noggin (30 ng/ml).  As shown in Fig. 2B, in the presence of 4 
Noggin, OCT treatment suppressed PRL and cAMP levels, while the actions of SOM 5 
reducing PRL and cAMP levels were reversed by Noggin.  BRC actions were not 6 
affected by Noggin treatment.  As shown in Fig. 2C, these Noggin effects were also 7 
enhanced in GH3 cells treated with FSK.  That is, in the presence of Noggin, OCT 8 
suppressed PRL secretion, but the effects of SOM were reversed.  BRC effects were 9 
not affected by addition of Noggin.  These findings suggest that the endogenous BMP 10 
system is active to modulate OCT and SOM actions for regulating PRL secretion in 11 
GH3 cells. 12 
We also investigated the effects of BMP-4 and Noggin on PRL mRNA levels 13 
in GH3 cells treated with FSK (Fig. 3).  FSK significantly enhanced mRNA 14 
expression of PRL, which was not directly influenced by treatment with Noggin or 15 
BMP-4.  BRC significantly suppressed the PRL mRNA levels in FSK-treated GH3 16 
cells.  The BRC effects on PRL mRNA levels were not affected by BMP-4 or Noggin.   17 
Although OCT alone did not affect PRL expression, PRL mRNA levels were 18 
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significantly reduced by OCT in cells treated with Noggin but not with BMP-4.  On 1 
the other hand, PRL mRNA levels were reduced by SOM alone, which was reversed by 2 
adding Noggin.  In addition, the reduction of PRL expression by SOM treatment was 3 
further suppressed by BMP-4 (Fig. 3).   4 
To investigate the mechanism by which neutralization of endogenous BMPs 5 
influenced the effects of somatostatin analogs on PRL secretion, expression of the key 6 
receptors D2R, SSTR-2 and SSTR-5 was evaluated by real-time PCR analysis.  As 7 
shown in Fig. 4A, D2R expression was not affected by BMP-4 and BMP-6 regardless 8 
of the presence of FSK.  However, SSTR-2 mRNA expression was downregulated by 9 
addition of BMP-4 and BMP-6, whereas SSTR-5 expression was upregulated by 10 
BMP-4 and BMP-6.  These changes were prominent when cells were activated with 11 
FSK.  It was thus thought that pretreatment with Noggin maintains SSTR-2 level but 12 
decreases SSTR-5 expression.  Therefore, endogenous BMP actions may be involved 13 
in enhancing SOM effects but impairing OCT effects on the reduction of PRL level.  14 
In addition, Id-1 mRNA levels induced by BMP-4 and -6, indicating BMP signaling 15 
activity, were also found to be enhanced by FSK treatment (Fig. 4B).  The 16 
phosphorylation of Smad1/5/8 signaling induced by BMP-4 and -6 was not directly 17 
affected by treatment with SOM or OCT (Fig. 4C), although BMP-4 and -6 changed 18 
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SSTR-2 and -5 expression differentially (Fig. 4A).             1 
 2 
3 
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Discussion 1 
 2 
In the present study, a unique action of the pituitary BMP system in the 3 
modulation of PRL secretion regulated by somatostatin analogs was uncovered in GH3 4 
cells expressing SSTRs and BMP system (Fig. 5).  Firstly, endogenous BMP actions 5 
are involved in augmenting PRL secretion, since BMP-4 and -6 increased PRL and 6 
cAMP levels and the effects were neutralized by a BMP-binding protein Noggin.  7 
Secondarily, BMPs modulate SSTR sensitivity of GH3 cells in an autocrine/paracrine 8 
manner.  Namely, BMP-4 and -6 reduced SSTR-2 expression but increased SSTR-5 9 
expression.  The effect of SOM230 (a SSTR-5-preferring agonist) that reduced PRL 10 
secretion induced by FSK was facilitated by adding BMP-4 and in turn blocked by 11 
Noggin.  On the contrary, in the presence of Noggin, OCT (a SSTR-2-preferring 12 
agonist) rather exerted an inhibitory effect on the PRL release.   13 
In the presence of BMP-4 actions, SSTR-2 expression could be 14 
downregulated, and therefore, OCT effects on PRL release remained latent regardless of 15 
the presence or absence of FSK.  This phenomenon was in contrast to the effects of 16 
BRC and SOM on the PRL release, since D2R was not affected by BMP-4 and SSTR-5 17 
was rather upregulated by BMP-4.  Noggin by itself had no specific effect on cAMP 18 
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level; however, in the presence of Noggin, OCT effects on cAMP and PRL reduction 1 
became apparent because Noggin could neutralize the activities of endogenous BMPs 2 
which suppress SSTR-2 expression.  It is thus suggested that the blockage of 3 
endogenous BMP actions by Noggin rescues SSTR-2 signaling but downregulates 4 
SSTR-5, leading to an increase in OCT sensitivity of GH3 cells.   5 
In addition, BMP-Smad signaling shown as Id-1 transcription was facilitated 6 
by stimulation with FSK in GH3 cells.  Certainly, BMP-4 action on increasing SSTR-5 7 
expression was apparent when cells were treated with FSK, and the BMP-4 effect on 8 
potentiating the SOM actions reducing PRL secretion was significant when cells were 9 
stimulated by FSK.  These findings also suggest that BMPs elicit differential actions in 10 
the regulation of PRL level dependent on cellular cAMP-PKA activity.   11 
The BMP system including BMP-4 has been shown to play important roles in 12 
initial development of the anterior pituitary involving lactotrope (Scully and Rosenfeld, 13 
2002).  Each of type I and type II receptor for BMPs exhibits serine/threonine kinase 14 
activity, in which several preferential combinations of BMP ligands and receptors have 15 
been recognized to date.  Since ALK-6 is not expressed in GH3 cells, the receptor pair 16 
of ALK-3 and BMPRII is likely to be the major functional complex for BMP-4 for 17 
regulating PRL and cAMP production. 18 
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Overexpression of the BMP-binding protein Noggin or dominant-negative 1 
ALK-3 in the anterior pituitary leads to arrest of the development of the 2 
Pit-1-expressing lineage (Scully and Rosenfeld, 2002).  BMP-4 is overexpressed in 3 
lactotrope adenomas derived from D2R-null mice as well as human prolactinomas 4 
(Paez-Pereda et al., 2003).  Moreover, Noggin expression is conversely downregulated 5 
in prolactinomas from D2R null mice (Paez-Pereda et al., 2003), suggesting that BMP-4 6 
promotes cell proliferation in lactotoropes in conjunction with Smad-estrogen receptor 7 
interaction.  In the present study, we discovered an interrelationship between BMP 8 
effects and SSTR expression for PRL secretion.  BMPs act to increase PRL release at 9 
least in part via a cellular cAMP-PKA pathway.  Hence, it is possible that the 10 
endogenous BMP system plays a key role in the modulation of SSTR sensitivity of 11 
lactotorope tumor cells in an autocrine/paracrine manner. 12 
Somatostatin acts by binding five subtypes of G protein–coupled receptors 13 
that are widely distributed in many endocrine and nonendocrine tissues.  The efficacy 14 
of somatostatin analogs is linked to the SSTR selectivity profile, in which binding 15 
capability to SSTR-2 and SSTR-5 appears critical (Shimon et al., 1997).  SSTR-2 and 16 
SSTR-5 are negatively coupled to adenylyl cyclase, the activation of which results in a 17 
reduction of intracellular cAMP levels (Reisine and Bell, 1995).  The SSTR effects are 18 
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further mediated by Ca++ influx through a direct action on Ca++ channels (Chen et al., 1 
1997) and/or indirectly through activating K+ channels (Takano et al., 1997).  The 2 
success of in vivo peptide-targeted therapy is highly dependent on the presence and on 3 
the localization in the tumor of a sufficient amount of the appropriate receptor.  In this 4 
regard, we recently reported the involvement of BMP system in corticotrope cells 5 
(Tsukamoto et al., 2010).  In that study, somatostatin analogs upregulated BMP-Smad 6 
signaling by augmenting BMPRII/ALK-3 expression as well as by reducing the 7 
expression of inhibitory Smad6/7 in corticotrope AtT20 cells.  However, the effects of 8 
SOM on BMP-4 signaling were significantly higher than the effects of OCT in AtT20 9 
cells, indicating the differences of SSTR affinities between two somatostatin analogs 10 
(Tsukamoto et al., 2010).  Similar to our current study on lactotrope cells, the 11 
interaction of BMP-Smad pathway and CRH receptor signaling was also functionally 12 
involved in controlling ACTH production from corticotrope cells in an 13 
autocrine/paracrine manner. 14 
Lactotrope adenomas are the most frequent pituitary tumors.  The main 15 
pharmacologic treatment of PRL-secreting adenomas is dopamine agonists (DA).  16 
However, treatment is ineffective in 10% to 15% of treated patients, even with the most 17 
potent cabergoline (Molitch, 2005; Gillam et al., 2006).  Although D2R is expressed in 18 
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nearly all prolactinomas and is the target for much current therapy, some patients are 1 
resistant to DA.  SSTR is known to be expressed in prolactinomas, the majority of 2 
which express SSTR-5 but not SSTR-2 (Jaquet et al., 1999).  This expression pattern 3 
indicates that established somatostatin analogs such as octreotide (OCT) and lanreotide, 4 
which bind primarily to SSTR-2, are much less effective for suppressing PRL secretion 5 
from prolactinomas compared with pasireotide (SOM), having a 40-fold greater binding 6 
affinity to SSTR-5 (Hofland et al., 2004). 7 
In clinical trials testing somatostatin analogs, the effects of cortistatin, a 8 
neuropeptide that has high homology with somatostatin and binds with high affinity to 9 
all SSTRs, on PRL suppression in prolactinoma patients were reported (Grottoli et al., 10 
2006).  BIM-23206, a SSTR-5-selective agonist (Fusco et al., 2008), was also reported 11 
to suppress PRL release in patients with DA-sensitive prolactinomas similar to 12 
cabergoline.  Another study on PRL-secreting adenomas also revealed significant 13 
effects of cortistatin and a SSTR-5 agonist on PRL reduction in most of the 14 
prolactinomas examined, whereas PRL inhibition by the SSTR-2 agonist was observed 15 
in only one case of prolactinoma (Rubinfeld et al., 2006).  These results support the 16 
notion that SSTR-5 primarily regulates PRL suppression by somatostatin in 17 
prolactinoma cells (Shimon et al., 1997).  In addition, the existence of novel mRNA 18 
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splice variants of the human SSTR-5 gene, having five and four transmembrane 1 
domains, was reported in different human tissues, including a prolactinoma 2 
(Duran-Prado et al., 2009).  Since these novel SSTR-5 variants have been found to 3 
show different patterns of cellular localization than that of the original isoform of 4 
SSTR-5, the altered expression may also be involved in pathophysiological sensitivity 5 
of SSTRs in prolactinomas. 6 
Collectively, this functional link between BMP-Smad signaling and SSTR 7 
actions may be involved in the individual tolerance to somatostatin analogs for 8 
controlling PRL secretion from prolactinomas (Fig. 5).  Somatostatin analogs with 9 
modified receptor subtype affinities with prolonged binding capacity would have the 10 
potential to be developed as new treatment modalities for functioning pituitary 11 
adenomas.  Otherwise, the establishment of regulatory methods of the endogenous 12 
BMP/Noggin system, which is a functional determinant for SSTR sensitivity, may be a 13 
future strategy for the treatment of DA-resistant prolactinomas.  Further study is 14 
needed to elucidate the detailed molecular mechanism by which BMPs differentially 15 
regulate SSTR expression by human prolactinomas. 16 
17 
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Figure Legends 1 
 2 
Fig. 1. Effects of BMPs and somatostatin analogs on prolactin secretion.  A) GH3 3 
cells (1 × 105 viable cells) were precultured in serum-free DMEM/F12.  The cells were 4 
then treated with BMP-4 (10-100 ng/ml), BMP-6 (10-100 ng/ml) and Noggin (10-100 5 
ng/ml).  After 24-h culture, the supernatants of culture media were collected, and 6 
prolactin (PRL) and cAMP levels were determined by specific enzyme immunoassays.  7 
For measurement of cAMP levels, cells were cultured with serum-free medium 8 
containing 0.1 mM of IBMX.  B) and C) GH3 cells (1 × 105 viable cells) were 9 
precultured in serum-free DMEM/F12.  Cells were treated with octreotide (OCT; 10 
0.1-10 µM), bromocriptine (BRC; 1-100 µM) or pasireotide (SOM; 0.1-30 µM) in the 11 
absence (B) or presence (C) of forskolin (FSK; 1 µM).  After 24-h culture, the culture 12 
media were collected, and PRL and cAMP levels were determined.  Results in all 13 
panels are shown as mean ± SEM of data from at least three separate experiments, each 14 
performed with triplicate samples.  The results were analyzed by ANOVA with 15 
Tukey-Kramer’s post hoc test or unpaired t-test.  For each result within a panel, *, P < 16 
0.05 vs. control group in each panel; and the values with different superscript letters are 17 
significantly different at P < 0.05. 18 
 19 
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Fig. 2. Effects of BMP-4 and Noggin on prolactin secretion regulated by 1 
somatostatin analogs in GH3 cells.  GH3 cells (1 × 105 viable cells) were precultured 2 
in serum-free DMEM/F12.  The cells were treated with octreotide (OCT; 1-10 µM), 3 
bromocriptine (BRC; 1-10 µM) and pasireotide (SOM; 1-10 µM) in combination with 4 
(A) BMP-4 (100 ng/ml) and (B, C) Noggin (30 ng/ml) in the absence or presence of 5 
forskolin (FSK; 1 µM).  After 24-h treatment, prolactin (PRL) and cAMP levels in 6 
culture media were determined by enzyme immunoassays.  For measurement of cAMP 7 
levels, cells were cultured with serum-free medium containing 0.1 mM of IBMX.  8 
Results in all panels are shown as mean ± SEM of data from at least three separate 9 
experiments, each performed with triplicate samples.  The results were analyzed by 10 
ANOVA with Tukey-Kramer’s post hoc test or unpaired t-test.  For each result within 11 
a panel, *, P < 0.05 vs. control group in each panel; and the values with different 12 
superscript letters are significantly different at P < 0.05. 13 
 14 
Fig. 3.  Effects of BMP-4 and Noggin on prolactin mRNA expression regulated by 15 
somatostatin analogs in GH3 cells.  GH3 cells (3 × 105 viable cells) were precultured 16 
in serum-free DMEM/F12.  The cells were treated with octreotide (OCT; 10 µM), 17 
bromocriptine (BRC; 10 µM) and pasireotide (SOM; 10 µM) in the absence or presence 18 
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of BMP-4 (100 ng/ml) and Noggin (30 ng/ml) and forskolin (FSK; 1 µM).  After 24-h 1 
culture, total cellular RNA was extracted and subjected to RT-PCR reaction.  The 2 
mRNA expression levels of prolactin (PRL) were quantified by real-time PCR analysis.  3 
The expression levels of target genes were standardized by RPL19 level in each sample.  4 
Results in all panels are shown as mean ± SEM of data from at least three separate 5 
experiments, each performed with triplicate samples.  The results were analyzed by 6 
ANOVA with Tukey-Kramer’s post hoc test or unpaired t-test.  For each result within 7 
a panel, *, P < 0.05 vs. control group in each panel; and the values with different 8 
superscript letters are significantly different at P < 0.05. 9 
 10 
Fig. 4.  Effects of BMPs on somatostatin receptors (SSTR) expression and effects 11 
of forskolin and somatostatin analogs on BMP receptor signaling in GH3 cells.  12 
A) GH3 cells (3 × 105 viable cells) were precultured in serum-free DMEM/F12.  The 13 
cells were treated with BMP-4 and BMP-6 (100 ng/ml) in the absence or presence of 14 
forskolin (FSK; 1 µM).  After 24-h culture, total cellular RNA was extracted and 15 
subjected to RT-PCR reaction.  The mRNA expression levels of dopamine type-2 16 
receptor (D2R), SSTR-2 and SSTR-5 were quantified by real-time PCR analysis.  The 17 
expression levels of target genes were standardized by RPL19 level in each sample.  18 
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B) After preculture, cells were treated with BMP-4 and BMP-6 (100 ng/ml) in the 1 
absence or presence of forskolin (FSK; 1 µM).  After 24-h culture, total cellular RNA 2 
was extracted and subjected to RT-PCR reaction.  The mRNA expression levels of 3 
Id-1 were quantified by real-time PCR analysis.  The expression levels of target genes 4 
were standardized by RPL19 level in each sample.  C) Cells (3 × 105 viable cells) were 5 
precultured in serum-free DMEM/F12.  After pretreatment with octreotide (OCT; 10 6 
μM) and pasireotide (SOM; 10 µM) for 1 h, the cells were treated with BMP-4 and 7 
BMP-6 (100 ng/ml) for 60 min.  The cell lysates were then subjected to SDS-PAGE 8 
immunoblotting (IB) analysis using anti-phosho-Smad1/5/8 antibody and anti-actin 9 
antibody.  The relative integrated density of each protein band was digitized and 10 
pSmad1/5/8 levels were normalized by actin level in each sample.  Results in all 11 
panels are shown as mean ± SEM of data from at least three separate experiments, each 12 
performed with triplicate samples.  The results were analyzed by ANOVA with 13 
Tukey-Kramer’s post hoc test or unpaired t-test.  For each result within a panel, *, P < 14 
0.05 vs. control group in each panel; and the values with different superscript letters are 15 
significantly different at P < 0.05. 16 
 17 
Fig. 5.  A possible interaction of BMP system and prolactin secretion in 18 
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lactotrope cells.  BMPs increased prolactin (PRL) secretion with increasing cAMP 1 
level by GH3 cells via proper BMP receptors (BMPRs), and the effects were neutralized 2 
by a BMP-binding protein Noggin.  BMPs reduced SSTR-2 expression but increased 3 
SSTR-5 expression in GH3 cells.  The effect of SOM230, which reduced PRL 4 
secretion induced by forskolin (FSK), was facilitated by BMP treatment but in turn 5 
blocked by adding Noggin.  On the contrary, in the presence of Noggin, OCT exerted 6 
an inhibitory effect on the PRL secretion.  BRC effects, which suppressed PRL and 7 
cAMP levels via dopamine D2 receptor (D2R), were not affected by BMP or Noggin 8 
treatment.  BMP signaling was also facilitated by FSK stimulation.  Thus, BMPs may 9 
play a key role in the modulation of SSTR sensitivity of lactotrope cells in an 10 
autocrine/paracrine manner. 11 
 12 
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